Ye Guo

机构：Shanghai East Hospital

发表论文 28 篇 · 总被引 90 次 · h-index 5

代表论文

• Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition) (2025 · European Journal of Nuclear Medicine and Molecular Imaging · 被引 18)
• Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study. (2023 · Journal of Clinical Oncology · 被引 11)
• Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced tumors. (2022 · Journal of Clinical Oncology · 被引 8)
• GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL). (2022 · Journal of Clinical Oncology · 被引 6)
• A phase 2 study of novel MDM2 inhibitor alrizomadlin (APG-115) with or without toripalimab in patients (pts) with advanced adenoid cystic carcinoma (ACC) or other solid tumors. (2025 · Journal of Clinical Oncology · 被引 5)
• Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial (2024 · Haematologica · 被引 5)